{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:31:13Z","timestamp":1793399473157,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2022307079"],"award-info":[{"award-number":["H2022307079"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Government-funded clinical medicine training excellence programme 2022","award":["ZF2022022"],"award-info":[{"award-number":["ZF2022022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02989-y","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:45:46Z","timestamp":1784807146000},"page":"3255-3265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in proteomics research related to semaglutide: evidence from humans and animals"],"prefix":"10.1007","volume":"49","author":[{"given":"Qiannan","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5087-349X","authenticated-orcid":false,"given":"Zhe","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"3","key":"2989_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","volume":"23","author":"MK Mahapatra","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM (2022) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews Endocr metabolic disorders 23(3):521\u2013539. https:\/\/doi.org\/10.1007\/s11154-021-09699-1","journal-title":"Reviews Endocr metabolic disorders"},{"key":"2989_CR2","doi-asserted-by":"publisher","first-page":"376509","DOI":"10.1155\/2011\/376509","volume":"2011","author":"B Portha","year":"2011","unstructured":"Portha B, Tourrel-Cuzin C, Movassat J (2011) Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Experimental diabetes Res 2011:376509. https:\/\/doi.org\/10.1155\/2011\/376509","journal-title":"Experimental diabetes Res"},{"issue":"12","key":"2989_CR3","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.3390\/cimb46120872","volume":"46","author":"I Papakonstantinou","year":"2024","unstructured":"Papakonstantinou I, Tsioufis K, Katsi V (2024) Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol 46(12):14514\u201314541. https:\/\/doi.org\/10.3390\/cimb46120872","journal-title":"Curr Issues Mol Biol"},{"issue":"8","key":"2989_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/diseases12080186","volume":"12","author":"AI Gad","year":"2024","unstructured":"Gad AI, Ibrahim NF, Almadani N et al (2024) Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial. Dis (Basel Switzerland) 12(8):186. https:\/\/doi.org\/10.3390\/diseases12080186","journal-title":"Dis (Basel Switzerland)"},{"issue":"1","key":"2989_CR5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1186\/s12872-025-05278-3","volume":"25","author":"S Sadraei","year":"2025","unstructured":"Sadraei S, Aarabi A, Firouzabadi R, S., et al (2025) Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 25(1):881. https:\/\/doi.org\/10.1186\/s12872-025-05278-3","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2989_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1021\/acs.jmedchem.5c01986","volume":"69","author":"L Tagliazucchi","year":"2026","unstructured":"Tagliazucchi L, Costi MP (2026) Mass Spectrometry Proteomics: A Key to Faster Drug Discovery. J Med Chem 69(1):30\u201371. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01986","journal-title":"J Med Chem"},{"issue":"5","key":"2989_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4331\/wjbc.v12.i5.57","volume":"12","author":"S Al-Amrani","year":"2021","unstructured":"Al-Amrani S, Al-Jabri Z, Al-Zaabi A, Alshekaili J, Al-Khabori M (2021) Proteomics: Concepts and applications in human medicine. World J Biol Chem 12(5):57\u201369. https:\/\/doi.org\/10.4331\/wjbc.v12.i5.57","journal-title":"World J Biol Chem"},{"key":"2989_CR8","doi-asserted-by":"publisher","first-page":"RP95595","DOI":"10.7554\/eLife.95595","volume":"13","author":"JG Van Vranken","year":"2024","unstructured":"Van Vranken JG, Li J, Mintseris J, Wei TY et al (2024) Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays. eLife 13:RP95595. https:\/\/doi.org\/10.7554\/eLife.95595","journal-title":"eLife"},{"issue":"11","key":"2989_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s41374-022-00830-7","volume":"102","author":"M Cui","year":"2022","unstructured":"Cui M, Cheng C, Zhang L (2022) High-throughput proteomics: a methodological mini-review. Lab Invest 102(11):1170\u20131181. https:\/\/doi.org\/10.1038\/s41374-022-00830-7","journal-title":"Lab Invest"},{"key":"2989_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ddtec.2021.06.006","volume":"39","author":"J Li","year":"2021","unstructured":"Li J, Smith LS, Zhu HJ (2021) Data-independent acquisition (DIA): An emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters. Drug discovery today Technol 39:49\u201356. https:\/\/doi.org\/10.1016\/j.ddtec.2021.06.006","journal-title":"Drug discovery today Technol"},{"issue":"8","key":"2989_CR11","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.mcpro.2024.100800","volume":"23","author":"K Fr\u00f6hlich","year":"2024","unstructured":"Fr\u00f6hlich K, Fahrner M, Brombacher E et al (2024) Data-Independent Acquisition: A Milestone and Prospect in Clinical Mass Spectrometry-Based Proteomics. Mol Cell proteomics: MCP 23(8):100800. https:\/\/doi.org\/10.1016\/j.mcpro.2024.100800","journal-title":"Mol Cell proteomics: MCP"},{"issue":"1","key":"2989_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12014-025-09572-2","volume":"23","author":"X Zou","year":"2025","unstructured":"Zou X, Wang L, Chen Y, Fu H, Gao Y, Liu B, Tan M, Zhai L (2025) In-depth analysis of data characteristics and comparative evaluation of dda and dia accuracy in label-free quantitative proteomics of biological samples. Clin Proteomics 23(1):2. https:\/\/doi.org\/10.1186\/s12014-025-09572-2","journal-title":"Clin Proteomics"},{"key":"2989_CR13","doi-asserted-by":"publisher","first-page":"564446","DOI":"10.3389\/fnmol.2020.564446","volume":"13","author":"KW Li","year":"2020","unstructured":"Li KW, Gonzalez-Lozano MA, Koopmans F, Smit AB (2020) Recent Developments in Data Independent Acquisition (DIA) Mass Spectrometry: Application of Quantitative Analysis of the Brain Proteome. Front Mol Neurosci 13:564446. https:\/\/doi.org\/10.3389\/fnmol.2020.564446","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"2989_CR14","doi-asserted-by":"publisher","first-page":"nwaf278","DOI":"10.1093\/nsr\/nwaf278","volume":"12","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Wang J, Sun A et al (2025) The coming era of proteomics-driven precision medicine. Natl Sci Rev 12(8):nwaf278. https:\/\/doi.org\/10.1093\/nsr\/nwaf278","journal-title":"Natl Sci Rev"},{"issue":"1","key":"2989_CR15","doi-asserted-by":"publisher","first-page":"e8792","DOI":"10.15252\/msb.20188792","volume":"17","author":"AL Richards","year":"2021","unstructured":"Richards AL, Eckhardt M, Krogan NJ (2021) Mass spectrometry-based protein-protein interaction networks for the study of human diseases. Mol Syst Biol 17(1):e8792. https:\/\/doi.org\/10.15252\/msb.20188792","journal-title":"Mol Syst Biol"},{"key":"2989_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2989_CR17","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160v","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160v","journal-title":"BMJ"},{"issue":"3","key":"2989_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.11124\/JBIES-23-00268","volume":"22","author":"TH Barker","year":"2024","unstructured":"Barker TH, Habibi N, Aromataris E et al (2024) The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid synthesis 22(3):378\u2013388. https:\/\/doi.org\/10.11124\/JBIES-23-00268","journal-title":"JBI Evid synthesis"},{"key":"2989_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB et al (2014) SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol 14:43. https:\/\/doi.org\/10.1186\/1471-2288-14-43","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2989_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41591-024-03355-2","volume":"31","author":"L Maretty","year":"2025","unstructured":"Maretty L, Gill D, Simonsen L et al (2025) Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat Med 31(1):267\u2013277. https:\/\/doi.org\/10.1038\/s41591-024-03355-2","journal-title":"Nat Med"},{"key":"2989_CR21","doi-asserted-by":"publisher","first-page":"1650729","DOI":"10.3389\/fendo.2025.1650729","volume":"16","author":"S Niu","year":"2025","unstructured":"Niu S, Chen S, Wu D, Wang C, Xu J, Yin J, Zhao Y (2025) Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study. Front Endocrinol 16:1650729. https:\/\/doi.org\/10.3389\/fendo.2025.1650729","journal-title":"Front Endocrinol"},{"issue":"9","key":"2989_CR22","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","volume":"31","author":"M Jara","year":"2025","unstructured":"Jara M, Norlin J, Kj\u00e6r MS et al (2025) Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med 31(9):3128\u20133140. https:\/\/doi.org\/10.1038\/s41591-025-03799-0","journal-title":"Nat Med"},{"issue":"1","key":"2989_CR23","doi-asserted-by":"publisher","first-page":"oeaf170","DOI":"10.1093\/ehjopen\/oeaf170","volume":"6","author":"CB Samaranayake","year":"2025","unstructured":"Samaranayake CB, Chen YC, Fang M et al (2025) GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling. Eur heart J open 6(1):oeaf170. https:\/\/doi.org\/10.1093\/ehjopen\/oeaf170","journal-title":"Eur heart J open"},{"key":"2989_CR24","doi-asserted-by":"publisher","first-page":"1095432","DOI":"10.3389\/fendo.2023.1095432","volume":"14","author":"R Zhu","year":"2023","unstructured":"Zhu R, Chen S (2023) Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice. Front Endocrinol 14:1095432. https:\/\/doi.org\/10.3389\/fendo.2023.1095432","journal-title":"Front Endocrinol"},{"key":"2989_CR25","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.2147\/JIR.S391859","volume":"15","author":"X Pan","year":"2022","unstructured":"Pan X, Yue L, Ban J, Ren L, Chen S (2022) Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice. J Inflamm Res 15:6409\u20136425. https:\/\/doi.org\/10.2147\/JIR.S391859","journal-title":"J Inflamm Res"},{"issue":"10","key":"2989_CR26","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacbts.2023.05.012","volume":"8","author":"C Withaar","year":"2023","unstructured":"Withaar C, Meems LMG, Nollet EE et al (2023) The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF. JACC Basic translational Sci 8(10):1298\u20131314. https:\/\/doi.org\/10.1016\/j.jacbts.2023.05.012","journal-title":"JACC Basic translational Sci"},{"key":"2989_CR27","doi-asserted-by":"publisher","first-page":"995007","DOI":"10.3389\/fendo.2022.995007","volume":"13","author":"L Yue","year":"2022","unstructured":"Yue L, Chen S, Ren Q, Niu S, Pan X, Chen X, Li Z, Chen X (2022) Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice. Front Endocrinol 13:995007. https:\/\/doi.org\/10.3389\/fendo.2022.995007","journal-title":"Front Endocrinol"},{"issue":"11","key":"2989_CR28","doi-asserted-by":"publisher","first-page":"7114","DOI":"10.18103\/mra.v13i11.7114","volume":"13","author":"C Zheng","year":"2025","unstructured":"Zheng C, Stone C, Muir K, Harris D, Sellke FW (2025) Proteomic Profiling of GLP-1-Mediated Cardioprotection in a Large Animal Model of Chronic Coronary Artery Disease. Med Res archives 13(11):7114. https:\/\/doi.org\/10.18103\/mra.v13i11.7114","journal-title":"Med Res archives"},{"issue":"9","key":"2989_CR29","doi-asserted-by":"publisher","first-page":"101277","DOI":"10.1016\/j.jacbts.2025.03.009","volume":"10","author":"R Basdas","year":"2025","unstructured":"Basdas R, Mart\u00ednez-Cereijo JM, Fern\u00e1ndez \u00c1L et al (2025) Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes. JACC Basic translational Sci 10(9):101277. https:\/\/doi.org\/10.1016\/j.jacbts.2025.03.009","journal-title":"JACC Basic translational Sci"},{"key":"2989_CR30","doi-asserted-by":"publisher","unstructured":"Yang Y, Pan X, Chen S (2024) Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice. Diabetes, metabolic syndrome and obesity: targets and therapy. 17:1217\u20131233. https:\/\/doi.org\/10.2147\/DMSO.S456336","DOI":"10.2147\/DMSO.S456336"},{"key":"2989_CR31","doi-asserted-by":"publisher","unstructured":"Wang S, Zhang M, Yang X, Chen S (2025) Protective Effect of Semaglutide on Obesity-Induced Renal Disease and Obesity-Induced Kidney Renal Clear Cell Carcinoma. Diabetes, metabolic syndrome and obesity: targets and therapy. 18:805\u2013818. https:\/\/doi.org\/10.2147\/DMSO.S498447","DOI":"10.2147\/DMSO.S498447"},{"issue":"1","key":"2989_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13098-025-01736-2","volume":"17","author":"S Wang","year":"2025","unstructured":"Wang S, Pan X, Liang R, Chen S (2025) Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip\/NLRP3 pathway. Diabetol Metab Syndr 17(1):164. https:\/\/doi.org\/10.1186\/s13098-025-01736-2","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2989_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13098-023-01023-y","volume":"15","author":"X Chen","year":"2023","unstructured":"Chen X, Ma L, Gan K, Pan X, Chen S (2023) Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice. Diabetol Metab Syndr 15(1):63. https:\/\/doi.org\/10.1186\/s13098-023-01023-y","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"2989_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3892\/ijmm.2025.5497","volume":"55","author":"Y Yang","year":"2025","unstructured":"Yang Y, Song L, Yu L, Zhang J, Zhang B (2025) Transcriptomics and proteomics characterizing the antioxidant mechanisms of semaglutide in diabetic mice with cognitive impairment. Int J Mol Med 55(4):56. https:\/\/doi.org\/10.3892\/ijmm.2025.5497","journal-title":"Int J Mol Med"},{"issue":"5","key":"2989_CR35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/oby.24274","volume":"33","author":"RH Choi","year":"2025","unstructured":"Choi RH, Karasawa T, Meza CA et al (2025) Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle. Obes (Silver Spring Md) 33(5):974\u2013985. https:\/\/doi.org\/10.1002\/oby.24274","journal-title":"Obes (Silver Spring Md)"},{"issue":"3","key":"2989_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2217\/fca-2016-0059","volume":"13","author":"L Han","year":"2017","unstructured":"Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S (2017) PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-\u03b1. Future Cardiol 13(3):259\u2013278. https:\/\/doi.org\/10.2217\/fca-2016-0059","journal-title":"Future Cardiol"},{"issue":"12","key":"2989_CR37","doi-asserted-by":"publisher","first-page":"a005058","DOI":"10.1101\/cshperspect.a005058","volume":"3","author":"P Lu","year":"2011","unstructured":"Lu P, Takai K, Weaver VM, Werb Z (2011) Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 3(12):a005058. https:\/\/doi.org\/10.1101\/cshperspect.a005058","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02989-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:01:38Z","timestamp":1793397698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02989-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2989"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02989-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}